The ISC has worked with CVS Caremark to revisit changes to its prior authorization forms that would have increased the administrative burden on practices, and patients with Blue Cross Blue Shield of South Carolina may not have to worry about switching to a self-administered biologic.
Search results for: osteoporosis
Improving Bone Mineral Density: Risedronate vs. Denosumab
Treatment with denosumab for patients with RA and glucocorticoid-induced osteoporosis led to greater increases in bone mineral density of the lumbar spine and hips of patients than treatment with risedronate.
ACR Insurance Subcommittee Chair Encourages Member Engagement
Rheumatology practices have a voice in payer advocacy through the Insurance Subcommittee of the ACR’s Committee on Rheumatologic Care.
The NIAMS Diversity Supplement Program Offers Researcher Funding
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is a component of the National Institutes of Health (NIH) that supports research into the causes, treatment and prevention of arthritis and musculoskeletal and skin diseases, as well as the training of basic and clinical scientists to carry out this research. NIAMS recognizes the…
The 2021 ACR Awards of Distinction & Distinguished Fellows
During ACR Convergence 2021 in early November, the ACR honored a group of individuals who have made significant contributions to rheumatology research, education and patient care, announcing the recipients of the ACR’s 2021 Awards of Distinction, as well as the group of Distinguished Fellows. recognized for their contributions. Three pediatric rheumatologists and one pediatric fellow…
At Least 1 Year on Bisphosphonates Needed for Fracture Prevention
(Reuters Health)—It takes 12.4 months of bisphosphonate therapy to prevent one nonvertebral fracture per 100 postmenopausal women with osteoporosis, a meta-analysis of randomized clinical trials suggests.1 Researchers examined data on 10 randomized clinical trials with a total of 23,384 women who had an osteoporosis diagnosis based on either existing vertebral fractures or a bone mineral…
What Rheumatologists Should Know About Childhood-Onset SLE & Vasculitis
ACR CONVERGENCE 2021—Many of the effects of childhood-onset systemic lupus erythematosus (cSLE) and vasculitis carry into adulthood and present adult rheumatologists with key differences in managing these patients after their transition from a pediatric to an adult provider. “The young adult with childhood-onset lupus is similar in many ways to adults with lupus, but there…
The 2021 ARP President’s Awards & Merit Awards
During ACR Convergence 2021 in early November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist profiles the winners of the ARP President’s and Merit Awards. ARP PRESIDENT’S AWARDS The ARP president can choose to honor ACR/ARP…
Case Report: Rheumatoid Arthritis Complicated by Large Granular Lymphocytic Leukemia
Large granular lymphocytic (LGL) leukemia is a rare, chronic, lymphoproliferative disorder of cytotoxic T cell or natural killer cell lineage with an annual incidence of 0.72 cases per 1 million people in the U.S.1 The most common subtype of LGL leukemia, T-LGL leukemia, follows an indolent disease course and accounts for approximately 85% of cases….
Atypical Giant Cell Arteritis Case Illustrates Diagnosis, Management Challenges
Giant cell arteritis (GCA) is a granulomatous vasculitis of large- and medium-sized arteries, usually affecting the cranial branches of the aortic arch. It is the most common vasculitis, with the highest risk factor being age. Accurate diagnosis and prompt initiation of therapy are of great importance to prevent serious complications, with the most feared being…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 57
- Next Page »